ANDPatent And • January 18th, 2006 • Omrix Biopharmaceuticals, Inc. • London
PATENT AND KNOW-HOW LICENSE AGREEMENTPatent And • March 28th, 2013 • Zoetis Inc. • Pharmaceutical preparations • New York
THIS PATENT AND KNOW-HOW LICENSE AGREEMENT (the "Agreement") is made effective as of February 6, 2013 (the "Effective Date"), by and between Pfizer Inc., a Delaware corporation having its principal place of business at 235 E. 42nd Street, New York, New York 10017 ("Pfizer") and Zoetis Inc., a Delaware corporation having its principal place of business at 5 Giralda Farms, Madison, NJ 07940 (the "Company"). Pfizer and the Company are sometimes referred to herein individually as a "Party" and collectively as the "Parties."
PATENT AND KNOW-HOW TRANSFER AGREEMENT Between GENERIS GMBH AM MITTLEREN MOOS 15 D-86167 AUGSBURG (IN THE FOLLOWING “GENERIS”) AND EXTRUDE HONE GMBH BERGHAUSER STR. 62 D-42859 REMSCHEID (IN THE FOLLOWING “EH”)Patent And • September 17th, 2013 • Voxeljet AG • Printing trades machinery & equipment
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
ContractPatent And • April 16th, 2021 • Gyroscope Therapeutics Holdings LTD • Biological products, (no disgnostic substances) • England
Certain confidential information contained in this document, marked by [**], has been omitted because the information (i) is not material and (ii) would likely cause competitive harm to the Company if publicly disclosed.
PATENT AND KNOW-HOW TRANSFER AGREEMENT Between GENERIS GMBH AM MITTLEREN MOOS 15 D-86167 AUGSBURG (IN THE FOLLOWING “GENERIS”) AND EXTRUDE HONE GMBH BERGHAUSER STR. 62 D-42859 REMSCHEID (IN THE FOLLOWING “EH”)Patent And • October 7th, 2013 • Voxeljet AG • Printing trades machinery & equipment
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Patent and Copyright Agreement for University of Idaho EmployeesPatent And • June 29th, 2015
As an employee of the University of Idaho, I acknowledge that I am subject to the policies and rules of the Regents of the University of Idaho published at: http://www.boardofed.idaho.gov/policies/documents/policies/v/vm_intellectual_property_0613.pdf
SECOND SIDE AMENDMENT TO PATENT AND KNOW-HOW EXCLUSVE SUBLICENSE AGREEMENT DATED AUGUST 18, 2005 AND ITS SIDE AMENDMENT DATED NOVEMBER 3, 2006.Patent And • March 19th, 2007 • Somanta Pharmaceuticals Inc. • Pharmaceutical preparations
This Second Side Amendment to patent and know-how exclusive sublicense Agreement (dated 8/18/05) (Sublicense Agreement) and its Side Amendment (dated 11/3/06) (Side Amendment) is entered into Wednesday, January 18, 2007 by Immunodex, a California corporation in Eureka, California (Immunodex) and Somanta Incorporated having business offices in Irvine, California and London, United Kingdom (Somanta).
PATENT AND KNOW-HOW LICENCE CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (1) AND COVION ORGANIC SEMICONDUCTORS GMBH (2)Patent And • December 15th, 2004 • Cambridge Display Technology, Inc. • Semiconductors & related devices • England
CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED FROM THIS DOCUMENT. SUCH OMISSIONS ARE NOTED BY “[**]”. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN SUBMITTED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION.
PATENT AND KNOW-HOW LICENSE AGREEMENT (THE COMPANY AS LICENSOR)Patent And • March 28th, 2013 • Zoetis Inc. • Pharmaceutical preparations • New York
THIS PATENT AND KNOW-HOW LICENSE AGREEMENT (the "Agreement") is made effective as of February 6, 2013 (the "Effective Date"), by and between Pfizer Inc., a Delaware corporation having its principal place of business at 235 E. 42nd Street, New York, New York 10017 ("Pfizer") and Zoetis Inc., a Delaware corporation having its principal place of business at 5 Giralda Farms, Madison, NJ 07940 (the "Company"). Pfizer and the Company are sometimes referred to herein individually as a "Party" and collectively as the "Parties."
DATED 2016 CAMBRIDGE ENTERPRISE LIMITED (1) (“CE”) and APCINTEX LIMITED (2) (“Licensee”) EXCLUSIVE PATENT AND NON-EXCLUSIVE KNOW-HOW LICENCE AGREEMENT Case No: [####]Patent And • April 21st, 2021 • Centessa Pharmaceuticals LTD • Pharmaceutical preparations • England
AMENDED AND RESTATED PATENT AND KNOW-HOW EXCLUSIVE LICENSE AGREEMENTPatent And • May 4th, 2007 • Devax Inc • Delaware
Mr. Jacques SEGUIN and Jean-Claude LABORDE are joint title owners of a patent issued on November 20, 1998 by the National Institute of Industrial Property of France, under the number 96 07245, entitled “Device permitting the treatment of bodily conducts at the level of a bifurcation” (“Underlying Patent”)1
THIS PATENT AND TECHNICAL INFORMATION CROSS-LICENSE AGREEMENT is entered into by NextLevel Communications, L.P. ("NLC") and General Instrument Corporation ("GI"), dated this ____ day of October, 1999, and effective as of the Effective Date (as defined...Patent And • October 29th, 1999 • Next Level Communications Inc • Telephone communications (no radiotelephone) • New York
PATENT AND KNOW-HOW LICENCE CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (1) AND COVION ORGANIC SEMICONDUCTORS GMBH (2)Patent And • July 30th, 2004 • Cambridge Display Technology, Inc. • England
CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED FROM THIS DOCUMENT. SUCH OMISSIONS ARE NOTED BY “[**]”. AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN SUBMITTED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION.
